BioAffinity CyPath Lung survivor surveillance announcement
CyPath Lung survivor surveillance announcement sparks 48% premarket surge
- Sep 1 8AM PR advances CyPath Lung for monitoring 680k+ US lung cancer survivors
- Focuses on post-curative treatment recurrence detection and new cancer screening
- Test delivers 92% sensitivity, 87% specificity, 99% NPV per prior trials
- Complements CT scans with noninvasive sputum analysis using flow cytometry, AI
- Builds on recent sales growth, AvMEDICAL deal, and July clinical framework
- Post 1-for-15 reverse split, news highlights expanded addressable market
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.